Healthcare Industry News: Eli Lilly
News Release - November 8, 2013
EMD Serono Announces Appointment of Paris Panayiotopoulos as President and Managing DirectorParis Panayiotopoulos to lead US operations of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany
ROCKLAND, Mass.--(Healthcare Sales & Marketing Network)--EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today the appointment of Paris Panayiotopoulos as President and Managing Director of EMD Serono. In this capacity, he will be responsible for driving the strategic direction of the US commercial organization, as well as managing the operations of the US subsidiary.
Mr. Panayiotopoulos comes to EMD Serono from the company’s Japan affiliate, Merck Serono, where he served as President and Managing Director since 2012.
“Paris is a strong customer and people oriented leader who brings a wealth of industry knowledge to this very important position for our organization,” said Belén Garijo, MD, President & CEO of Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. “He is an internal talent with a proven track record of driving improved business performance and developing quality leadership teams. We are truly excited to have Paris take over this important and strategic role for the company.”
Mr. Panayiotopoulos joined Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany in 2004 and has since held positions of increasing responsibility across multiple franchises and regions, including Director of Global Marketing, Global Commercial Team Leader, Head of Regional Operations and Head of the COO Office. Prior to this, Mr. Panayiotopoulos was at Eli Lilly & Co based in the UK.
“I am thrilled to have the opportunity to lead such a dedicated and driven organization in such a strategically important market for our Company,” said Mr. Panayiotopoulos. “I look forward to making great things happen with the talented employees of EMD Serono through our innovative, research-driven, specialty business to help patients live a better life.”
Mr. Panayiotopoulos has a BS in chemistry from the University College of London, and an MSc from Cranfield Business School of Management.
About EMD Serono, Inc.
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a specialized biopharmaceutical company dedicated to developing therapies with groundbreaking potential. The company has strong market positions in neurology, endocrinology and in reproductive health. In addition, EMD Serono has an enduring commitment to solve the unsolvable, with state-of-the-art science dedicated to developing new therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology. With a long-standing history of industry expertise and a dedication to shape the future of healthcare, the company’s US footprint continues to grow, with approximately 1,000 employees around the country and fully integrated commercial, clinical and research operations in the company’s home state of Massachusetts.
For more information, please visit www.emdserono.com
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a global pharmaceutical, chemical and life science company with total revenues of € 11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 38,000 employees in 66 countries. Its success is characterized by innovations from entrepreneurial employees. Merck KGaA's operating activities come under the umbrella of Merck KGaA, Darmstadt, Germany, in which the Merck family holds an approximately 70% interest and shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
Worldwide there are two separate companies that bear the name “Merck”, the original Merck KGaA from Darmstadt, Germany, the oldest pharmaceutical and chemical company in the world, and the pharmaceutical company Merck & Co. in the United States. The rights to the name and trademark MERCK in North America (USA and Canada) lie with Merck & Co., the former U.S. subsidiary of Merck, whereas Merck KGaA operates in North America under the umbrella brand EMD. In the rest of the world, Merck KGaA owns the rights to the Merck name and trademark. This press release was distributed by Merck KGaA, Darmstadt, Germany.
Source: EMD Serono
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsEMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study